PMID- 27215507
OWN - NLM
STAT- MEDLINE
DCOM- 20171113
LR  - 20220331
IS  - 1532-3064 (Electronic)
IS  - 0954-6111 (Linking)
VI  - 115
DP  - 2016 Jun
TI  - Efficacy of adalimumab in sarcoidosis patients who developed intolerance to 
      infliximab.
PG  - 72-7
LID - S0954-6111(16)30070-1 [pii]
LID - 10.1016/j.rmed.2016.04.011 [doi]
AB  - BACKGROUND: Tumor necrosis factor-alpha (TNF-alpha) inhibitors are regarded as the 
      third-line therapy in sarcoidosis, the first choice generally being infliximab. 
      To date, data regarding response to adalimumab in sarcoidosis patients intolerant 
      to infliximab are lacking. The objective of this retrospective observational 
      study was to establish if adalimumab could achieve stabilization or improvement 
      of the disease in refractory sarcoidosis patients who developed intolerance to 
      infliximab. MATERIAL AND METHODS: Sarcoidosis patients referred to St Antonius 
      Interstitial Lung Diseases Center of Excellence, Nieuwegein, The Netherlands, 
      between January 2008 and April 2015 who switched from infliximab to adalimumab 
      were included. Changes in organ function, inflammatory biomarker levels, and 
      adverse events were retrieved from medical records. RESULTS: Out of 142 
      infliximab treated patients, 18 (13%) had to discontinue treatment due to 
      antibody formation or severe adverse events and switched to adalimumab therapy. 
      Organ function improved in 7 patients (39%), was stable in 6 patients (33%), and 
      worsened in 5 patients (28%) after 12 months of treatment or after 6 months if 
      evaluation after 12 months was not available (n = 4). In none of the patients 
      biomarker levels of soluble interleukin-2 receptor (sIL-2R) deteriorated. Median 
      decrease in sIL-2R was 3614 pg/mL. Most reported adverse event was infection 
      (n = 10). CONCLUSIONS: Adalimumab is an effective alternative for patients 
      intolerant to infliximab. The switch to adalimumab achieved clinical improvement 
      in 39% and stabilization in 33% of patients intolerant to infliximab. Further 
      research is needed to develop guidelines on how to use adalimumab for sarcoidosis 
      in terms of dosing regimen.
CI  - Copyright (c) 2016 Elsevier Ltd. All rights reserved.
FAU - Crommelin, Heleen A
AU  - Crommelin HA
AD  - Interstitial Lung Diseases Center of Excellence, Department of Pulmonology, St 
      Antonius Hospital, Nieuwegein, The Netherlands; Department of Clinical Pharmacy, 
      St Antonius Hospital, Nieuwegein, The Netherlands.
FAU - van der Burg, Leone M
AU  - van der Burg LM
AD  - Interstitial Lung Diseases Center of Excellence, Department of Pulmonology, St 
      Antonius Hospital, Nieuwegein, The Netherlands; Science Department, University 
      College Roosevelt, Middelburg, The Netherlands.
FAU - Vorselaars, Adriane D M
AU  - Vorselaars AD
AD  - Interstitial Lung Diseases Center of Excellence, Department of Pulmonology, St 
      Antonius Hospital, Nieuwegein, The Netherlands.
FAU - Drent, Marjolein
AU  - Drent M
AD  - Interstitial Lung Diseases Center of Excellence, Department of Pulmonology, St 
      Antonius Hospital, Nieuwegein, The Netherlands; Department of Pharmacology and 
      Toxicology, Faculty of Health, Medicine and Life Sciences, Maastricht University, 
      The Netherlands.
FAU - van Moorsel, Coline H M
AU  - van Moorsel CH
AD  - Interstitial Lung Diseases Center of Excellence, Department of Pulmonology, St 
      Antonius Hospital, Nieuwegein, The Netherlands; Division of Heart and Lungs, 
      University Medical Center Utrecht, The Netherlands.
FAU - Rijkers, Ger T
AU  - Rijkers GT
AD  - Science Department, University College Roosevelt, Middelburg, The Netherlands; 
      Department of Medical Microbiology and Immunology, St Antonius Hospital, 
      Nieuwegein, The Netherlands.
FAU - Deneer, Vera H M
AU  - Deneer VH
AD  - Interstitial Lung Diseases Center of Excellence, Department of Pulmonology, St 
      Antonius Hospital, Nieuwegein, The Netherlands; Department of Clinical Pharmacy, 
      St Antonius Hospital, Nieuwegein, The Netherlands. Electronic address: 
      v.deneer@antoniusziekenhuis.nl.
FAU - Grutters, Jan C
AU  - Grutters JC
AD  - Interstitial Lung Diseases Center of Excellence, Department of Pulmonology, St 
      Antonius Hospital, Nieuwegein, The Netherlands; Division of Heart and Lungs, 
      University Medical Center Utrecht, The Netherlands.
LA  - eng
PT  - Journal Article
PT  - Observational Study
DEP - 20160423
PL  - England
TA  - Respir Med
JT  - Respiratory medicine
JID - 8908438
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Antirheumatic Agents)
RN  - 0 (Receptors, Interleukin-2)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - B72HH48FLU (Infliximab)
RN  - FYS6T7F842 (Adalimumab)
SB  - IM
MH  - Adalimumab/*pharmacology
MH  - Adult
MH  - Aged
MH  - Antibodies, Monoclonal
MH  - Antibodies, Monoclonal, Humanized/adverse effects/therapeutic use
MH  - Antirheumatic Agents/*pharmacology
MH  - Drug Hypersensitivity
MH  - Female
MH  - Humans
MH  - Infliximab/*adverse effects
MH  - Male
MH  - Middle Aged
MH  - Netherlands/epidemiology
MH  - Receptors, Interleukin-2
MH  - Retrospective Studies
MH  - Sarcoidosis/diagnosis/*drug therapy/metabolism
MH  - Treatment Outcome
MH  - Tumor Necrosis Factor-alpha/adverse effects/*antagonists & inhibitors/metabolism
MH  - Vital Capacity/drug effects
OTO - NOTNLM
OT  - Adalimumab
OT  - Anti-TNF-alpha
OT  - Infliximab
OT  - Sarcoidosis
EDAT- 2016/05/25 06:00
MHDA- 2017/11/14 06:00
CRDT- 2016/05/25 06:00
PHST- 2015/11/23 00:00 [received]
PHST- 2016/04/08 00:00 [revised]
PHST- 2016/04/21 00:00 [accepted]
PHST- 2016/05/25 06:00 [entrez]
PHST- 2016/05/25 06:00 [pubmed]
PHST- 2017/11/14 06:00 [medline]
AID - S0954-6111(16)30070-1 [pii]
AID - 10.1016/j.rmed.2016.04.011 [doi]
PST - ppublish
SO  - Respir Med. 2016 Jun;115:72-7. doi: 10.1016/j.rmed.2016.04.011. Epub 2016 Apr 23.